Beacon says gene therapy succeeds in key trial of rare eye disease XLRP

Beacon Therapeutics has succeeded in a gene therapy clinical trial for X-linked retinitis pigmentosa (XLRP), a rare genetic eye disease, achieving results where major drugmakers like Johnson & Johnson and Biogen have failed.

This Wire brief sits within Fusion42's coverage of Biotech and Diagnostics, and 2 sources have reported it.